Pfizer COVID-19 clinical trials: antiviral PF-07321332 and Pfizer antiviral PF-07304814
… Pfizer researching oral and IV COVID-19 antiviral therapies PF-07321332 and PF-07304814

Pfizer Launches Phase 1 Clinical Trial For Oral COVID-19 Antiviral Drug

Pfizer seeks to expand COVID-19 drug portfolio by creating novel antivirus therapies

Pfizer seeks to expand COVID-19 drug portfolio by creating novel antivirus therapies

PF-07321332 is a protease inhibitor

Pfizer is an innovative leader in the global battle against COVID-19

  • Individuals unable to be vaccinated due to other healthcare issues would have an important option if they were diagnosed with COVID-19
  • The product would be a go-to option in the event vaccinated individuals became infected by the coronavirus
  • An oral agent could prevent persons from being admitted to hospitals or needing to be treated with IV therapies in an outpatient setting -both more costly and less convenient than an oral therapy option
  • Payers would embrace the care, cost and convenience attributes of the oral formulation for their members
Pfizer is a global leader in developing vaccines and antiviral therapies to prevent or treat COVID-19 infection

Learning more about SARS-CoV-2 and developing multiple treatment options is a top priority